Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10353MR)

This product GTTS-WQ10353MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17A&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 10673
UniProt ID Q16552; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10353MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1973MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ4371MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ8138MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ13361MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ4655MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ2773MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ11301MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ5793MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW